Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-FLT3 nanoparticles for acute myeloid leukemia: Preclinical pharmacology and pharmacokinetics.

Journal of controlled release : official journal of the Controlled Release Society - 10 Aug 2020

Park Mincheol, Vaikari Vijaya Pooja, Lam Albert T, Zhang Yong, MacKay John Andrew, Alachkar Houda

Abstract excerpt

FLT3 receptor is an important therapeutic target in acute myeloid leukemia due to high incidence of mutations associated with poor clinical outcome. Targeted therapies against the FLT3 receptor, including small-molecule FLT3 tyrosine kinase inhibitors (TKIs) and anti-FLT3 antibodies, have demonstrated promising preclinical and even clinical efficacy. Yet, even with the current FDA approval for two FLT3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Elastin
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Nanoparticles

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 32428520
DOI: 10.1016/j.jconrel.2020.05.021
PMCID: PMC7473778

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-FLT3 nanoparticles for acute myeloid leukemia: Preclinical pharmacology and pharmacokinetics.PMID 32428520Read ↗

Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles.Semantic proximity Read ↗

Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia.Semantic proximity Read ↗

The role of FLT3 kinase as an AML therapy target.Semantic proximity Read ↗

Evolving paradigms in targeting FLT3 for acute myeloid leukemia therapy.Semantic proximity Read ↗

A Modular Layer-by-Layer Nanoparticle Platform for Hematopoietic Progenitor and Stem Cell TargetingSemantic proximity Read ↗

Dual-functional Nanocarrier for Improved Immunochemotherapy of Acute Myeloid LeukemiaSemantic proximity Read ↗

Intracellular Delivery of Peptides and Proteins with an Engineered Membrane Translocation DomainSemantic proximity Read ↗

Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC).Semantic proximity Read ↗

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.Semantic proximity Read ↗

[Possibility of targeting FLT3 kinase for the treatment of leukemia].Semantic proximity Read ↗

Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10.Semantic proximity Read ↗

Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.